Class & Mechanism
CagriSema refers to the co-administration of two GLP-1 receptor agonists, Cagrilintide and Semaglutide. Both peptides are long-acting analogs of the incretin hormone glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, delay gastric emptying, and increase satiety. The combination aims to enhance glycemic control and promote weight loss more effectively than monotherapy.
Research-documented benefits
Local corpus: silent.
General-knowledge benefits
– Improved glycemic control in type 2 diabetes mellitus (T2DM) patients [1].
– Enhanced weight reduction compared to monotherapy, with potential additional benefits in glycemic control [2].
– Reduced cardiovascular risk, as observed with individual GLP-1 receptor agonists [3].
– Delayed gastric emptying leading to increased satiety and decreased food intake [4].
Typical injectable protocol
The protocol for CagriSema would involve injecting both Cagrilintide and Semaglutide subcutaneously. The doses mentioned are 5+5 mg and 10+10 mg tiers for each peptide, respectively. The frequency of administration would align with the individual peptides' protocols, which are typically once-weekly for both Cagrilintide and Semaglutide. The cycle length would be determined on an individual basis, considering treatment goals and response to therapy.
Key risks / contraindications
– Gastrointestinal side effects such as nausea, vomiting, and diarrhea are common with GLP-1 receptor agonists.
– There is a risk of hypoglycemia, especially when used in combination with other glucose-lowering medications.
– Acute gallbladder disease has been associated with GLP-1 receptor agonists.
– Not recommended in patients with a history of pancreatitis or thyroid C-cell tumors.
Bottom line
CagriSema represents an experimental approach to enhance the therapeutic effects of GLP-1 receptor agonists in conditions like T2DM and obesity. Its use is currently investigational and should be undertaken with careful consideration of potential risks and benefits.
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- Basal Insulin Glargine 100 U_mL Versus 300 U_mL in Type 2 Diabetes
- Contemporary Diagnosis and Management of Obesity
- From rapalogs to anti-aging formula
- GLP-1 Receptor Agonists in Type 2 Diabetes
- GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
- Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
- Handbook of Clinical Nutrition and Aging
- Hazzard's Geriatric Medicine and Gerontology
- Hormone Therapy in Cancer and Aging-related Disorders
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- Incretin-Based Therapies for Type 2 Diabetes
- Incretin-Based Therapy_ From Human Physiology to Clinical Treatment
- Kosmetik für Ärzte und Apotheker
- Metabolic Syndrome_ Underlying Mechanisms and Drug Therapies
- Neurocritical Care
- Nutrition in Mental Health_ A Handbook
- Peptide Protocols Volume One — William A Seeds MD
- Pharmacology
- Pituitary Disorders
- Platelets
- Pulmonary Diseases and Disorders
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- Surgical Oncology_ Evidence-Based Approaches
- Surgical versus medical therapy of prolactinomas
- Textbook of Natural Medicine
- The AI Revolution in Medicine_ GPT-4 and Beyond
- The discovery and development of liraglutide and semaglutide
- The role of bile acids in the pathophysiology and treatment of type 2 diabetes
- Two incretin hormones, GIP and GLP-1_ similarities and differences